In an interview with Stock-Sector, Dr. Clarke explains how Pulmatrix is targeting major markets
with the iSPERSE technology platform that delivers drugs to the lungs more efficiently.
NEW YORK, NY – June 2, 2016 Stock-Sector.com, an online source of news about
Clarke, PhD, CEO of Pulmatrix.
In the interview, Dr. Clarke describes the history of Pulmatrix, and explains why the company
technology and pipeline offers “an obvious value proposition” for investors.
Trained as a biomedical engineer with a PhD in pulmonary physiology, Dr. Clarke has worked on
inhaled drug delivery for about 20 years. His initial research led to an aerosol that, when inhaled,
reduced the chances that a person would spread respiratory diseases to others. More important, it
also had a therapeutic, antiinflammatory effect.
Pulmatrix began to develop that aerosol to help treat chronic pulmonary obstructive disease
(COPD). But Dr. Clarke realized that a dry powder formulation would work even better. As a
company with a high percentage of engineers, “we had the expertise to transfer from aerosol to
dry powder,” he explains. “This novel technology we call iSPERSE allows us to deliver drugs
The company now has an extensive pipeline of inhaled drug candidates that reveal the “real
value” of Pulmatrix, Dr. Clarke says. The lead program is for COPD, “which affects tens of
millions of patients, with an over $25 billion market,” Dr. Clarke explains. If an ongoing analysis
of clinical data shows the expected results, it could trigger a licensing agreement with a major
pharma partner, with a fast track to approval in Europe. “It can go very rapidly,” he says.
Next in the pipeline are inhaled drug candidates to fight lung infections and idiopathic pulmonary
fibrosis. Each one could be either developed with a partner or by Pulmatrix on its own. “The
further we go ourselves, the greater the value proposition for Pulmatrix,” Dr. Clarke says in the
In addition, the pipeline will continue to grow. “We are thinking about novel therapeutics we can
enable with our technology,” Dr. Clarke says.
See the full video interview here: https://youtu.be/m_Ei9PKTIOM